BRAF and neoplasm: Over 80% of DEN-initiated tumour samples carried an activating hotspot driver mutation in either Hras or Braf. The remaining ∼20% of samples carried a potentially activating hotspot mutation in Egfr, one of the upstream receptor tyrosine kinases that can regulate the Ras signalling pathway.